IP Verse

Sloan Kettering Institute For Cancer Research competitive analysis

Loading summary...

Latest patents of Sloan Kettering Institute For Cancer Research opposed by its competitors

Explore Sloan Kettering Institute For Cancer Research's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 23, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3533792
May 5, 2021Crystalline Forms Of An Androgen Receptor Modulator1
EP3348553
Jul 8, 2020Crystalline Forms Of An Androgen Receptor Modulator2
EP2858985
Apr 18, 2018Crystalline Forms Of An Androgen Receptor Modulator3

Latest publications and patents of Sloan Kettering Institute For Cancer Research New

Explore the latest publications and patents granted to Sloan Kettering Institute For Cancer Research, showcasing their recent innovations and technological advancements.

Last updated on: Oct 17, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Sloan Kettering Institute For Cancer Research

EP3533792
May 5, 2021Crystalline Forms Of An Androgen Receptor ModulatorOpposition Rejected
EP3348553
Jul 8, 2020Crystalline Forms Of An Androgen Receptor ModulatorRevoked
EP2858985
Apr 18, 2018Crystalline Forms Of An Androgen Receptor ModulatorOpposition Rejected

Latest PTAB cases involving Sloan Kettering Institute For Cancer Research

Discover the latest PTAB cases involving Sloan Kettering Institute For Cancer Research, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 23, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Sloan Kettering Institute For Cancer Research

IPR2023-00070Oct 18, 2022BLUEBIRD BIOSLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision
IPR2023-00074Oct 18, 2022BLUEBIRD BIOSLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision
IPR2015-01719Aug 13, 2015KITE PHARMASLOAN KETTERING INSTITUTE FOR CANCER RESEARCHFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Sloan Kettering Institute For Cancer Research with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 23, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH - 6 - 3
BLUEBIRD BIO - 102 -
GENERICS UK214 - - -
KITE PHARMA - 11 -